VALUE ADDED MEDICINES- WHAT VALUE REPURPOSED MEDICINES MIGHT BRING TO SOCIETY?

Author(s)

Rémuzat C1, Toumi M2
1Creativ-Ceutical, Paris, France, 2Faculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Marseille, France

OBJECTIVES: Value added medicines are defined as “medicines based on known molecules that address health care needs and deliver relevant improvements for patients, health care professionals and/or payers”. Study objective was to assess from health care providers’, patients’, regulators’ and payers’ perspective which value drug repurposing might bring to society. METHODS: Interviews were conducted with health care providers, patients and payers following presentation of key examples of value added medicines to assess how value added medicines might respond to their needs and society needs. RESULTS: Value added medicines may first represent an opportunity to address health care system inefficiencies such as irrational use of medicines (e.g. through new drug formulations or drug combinations improving adherence issues of already available therapies or through drug repositioning and drug reformulations for specific patient groups contributing to limit off-label use of medicines), inappropriate treatment options (e.g. by tailoring and expanding access of well-known therapies to particular patient subgroups’ needs), shortage of mature products by creating new market attractiveness of mature products, geographical inequity in drug access (e.g. new drug formulations for hospital-only medicines which could be used in out-patient settings, thus improving access in remote rural areas). Value added medicines may also represent an opportunity to better address health care provision and organisation and could contribute to reduction and re-allocation in health care use. Finally, in the current cost-constraint environment, value added medicines may represent an opportunity to create an intermediate step before switching to costly products and reduce budget impact. CONCLUSIONS: Value added medicines represent an opportunity for society to address a number of drug related health care inefficiencies and also present an opportunity to deliver better health to patients, to enhance health care system efficiency and contribute to the sustainability of the health care systems.

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PHP140

Topic

Organizational Practices, Real World Data & Information Systems

Topic Subcategory

Academic & Educational, Health & Insurance Records Systems

Disease

Multiple Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×